Dendreon files in US for prostate cancer vaccine

Dendreon Corp has completed its US regulatory submission for its closely watched experimental prostate cancer vaccine, the company said on Monday, sending shares higher. Dendreon previously said it expected to seek US approval for Provenge in November and that it expected regulators to respond by mid-2010. If approved, Provenge would be the first "therapeutic" cancer vaccine. While conventional vaccines prevent disease, Provenge treats the condition. "With the (application) submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," Dendreon Chief Executive Mitchell Gold said in a statement. Dendreon shares, which have soared 10-fold since March, were up 4.8 per cent at $26.48 in premarket trading.